Leerink Raises Price Target as Roivant (ROIV) Accelerates Drug Development Pipeline [Yahoo! Finance]
Roivant Sciences Ltd. (ROIV)
Company Research
Source: Yahoo! Finance
11, Leerink Partners boosted its price target for Roivant Sciences Ltd. (NASDAQ:ROIV) to $32 from $29, keeping an Outperform rating on the company's shares. The firm highlighted lower estimated operational expenses in the years ahead than previously modeled, resulting in reduced expected losses and significant profitability beginning in fiscal year 2029. By the end of 2028, Roivant's “Next 36 Month vision” anticipates at least three commercial launches, four or more NDA/BLA submissions, no less than eight crucial readouts, and at least three proof-of-concept evaluations. Roivant Sciences Ltd. (NASDAQ:ROIV) has also advanced the development schedules for its primary therapeutic candidates, including brepocitinib, with a New Drug Application filing for dermatomyositis slated in early 2026 along with a possible commercial launch in early 2027. Furthermore, the Phase III trial for brepocitinib in non-infectious uveitis has reached full enrollment ahead of time, with topline results ex
Show less
Read more
Impact Snapshot
Event Time:
ROIV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ROIV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ROIV alerts
High impacting Roivant Sciences Ltd. news events
Weekly update
A roundup of the hottest topics
ROIV
News
- Vivek Ramaswamy turns to conservative youth to shape the movement's next phase, analyzes 2026 races [FOX News]FOX News
- Roivant Sciences (NASDAQ:ROIV) had its "buy" rating reaffirmed by analysts at Guggenheim.MarketBeat
- Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million? [Yahoo! Finance]Yahoo! Finance
- Immunovant (IMVT) Is Up 14.0% After Roivant-Backed $550 Million Equity Raise For IMVT-1402 - Has The Bull Case Changed? [Yahoo! Finance]Yahoo! Finance
- Roivant Sciences (NASDAQ:ROIV) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $24.00 to $33.00. They now have a "buy" rating on the stock.MarketBeat
ROIV
Earnings
- 11/10/25 - Beat
ROIV
Sec Filings
- 1/14/26 - Form 4
- 1/12/26 - Form 144
- 12/31/25 - Form 4
- ROIV's page on the SEC website